Alzheimer’s Disease Archives - DelveInsight

Alzheimer’s Disease

pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $...

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concernsThe FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had...


recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g
Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celle...

Researchers call out Gilead over the diversity of remdesivir trialsResearchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluat...


recent-Pharma-news-and-happenings
Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline m...

Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibodyThe Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If every...


pharma-news
Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Update...

Amylyx Pharmaceuticals grabs USD 30 Million Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral s...


What are the 10 early signs of Alzheimer’s that are overlooked?

Alzheimer’s is a brain disease, associated with the degeneration of brain cells. It is an irreversible and progressive disease that generally affects people aged above 65 years but in very rare ca...


Digital therapeutics
Potential of Digital therapeutics and increasing CVDs

The 21st century has been a remarkable century for humankind, as a lot of innovation, research and development has taken place in the field of healthcare, due to which we have been able to increas...


Pharma News
Tepezza receives approval; a new way to treat Alzheimer’s

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid EyeTepezza (teprotumumab-trbw) is the first-ever treatment appr...


Alzheimer's Disease Market Infographic
Alzheimer’s Disease Market Infographic

Alzheimer's Disease Market InfographicIt's is the end of Alzheimer's Awareness Month, but our hope for a cure for this disease will not end.They may not remember us, but we need to remem...


Pharma News
Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes.Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indic...


the business cocktail lemborexant
The Business Cocktail

EISAI now solely responsible for lemborexantEisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and co...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.